SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cambridge Antibody Technology Group
An SI Board Since December 1999
Posts SubjectMarks Bans
625 23 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
500Only suggestion I have seen is the thought that the Vioxx withdrawal might benefnigel bates-10/1/2004
499Any news in England to justify the surge? Or is the buying in anticipation of thubi_dooby_doo-9/30/2004
498Cambridge Antibody Technology Announces Financial Results for the Nine Months EnA.J. Mullen-9/30/2004
497New Drug Candidate for Severe Asthma From Cambridge Antibody Technology Starts CA.J. Mullen-9/30/2004
496Bit more on HGS-ETR1 and 2 Message 20580660 ...and following post.nigel bates-9/29/2004
495FDA makes safety revisions in Humira label: medscape.com Cheers, Tucktuck-9/16/2004
494HGSI starts PII for CAT's TRAIL-R1 agonist mAb (in NSLC) Message 20498399nigel bates-9/8/2004
493Cambridge Antibody Technology Announces Financial Results for the Nine Months Ennigel bates-9/8/2004
492New Drug Candidate for Severe Asthma From Cambridge Antibody Technology Starts Cnigel bates-9/8/2004
491HGSI put Kirin TRAIL R2 agonist mAB into the clinic - Message 20442342 <i>nigel bates-8/24/2004
490>>ABBOTT PARK, Ill., Aug. 10 /PRNewswire-FirstCall/ -- The U.S. Food and Dtuck-8/10/2004
489<pre>Evolutec Group PLC 2 August 2004 EVOLnigel bates-8/2/2004
488>>NEW YORK, July 29 /PRNewswire-FirstCall/ -- New Phase II study results otuck-7/29/2004
487<i> -- Worldwide HUMIRA sales were $203 million in the second quarter, nigel bates-7/9/2004
486Preliminary Data From Two Clinical Trials Demonstrate Abbott Laboratories' Hkeokalani'nui-6/14/2004
485ReAct Study Shows Abbott's Humira(R) (Adalimumab) Significantly Reduces Signnigel bates-6/10/2004
484From the Peptech first half (end 31st March) report; sadly doesn't give any nigel bates-6/9/2004
483Abbott Laboratories Announces Positive Results of Two Clinical Trials of HUMIRA(nigel bates-5/18/2004
482Abbott Laboratories' New Investigational Anti-Interleukin-12 (IL-12) Fully Hkeokalani'nui-5/17/2004
481[Re: GDF-8] Biochem Biophys Res Commun. 2004 Mar 12;315(3):525-31. Related Arkeokalani'nui-5/17/2004
480<pre>INTERIM STATEMENT OF RESULTS FOR THE SIX MONTHS ENDED 31 MARCH 20nigel bates-5/17/2004
479Cambridge Antibody Technology Interim Results for the Six Months Ended 31 March nigel bates-5/17/2004
478Swine ! <g>nigel bates-5/8/2004
477IL-12/ABT is part of the abt/catg arrangement. So I suppose abt will just deductrkrw-5/7/2004
476Hadn't noticed this before, from pdli's 10k: <i>Anti- IL-12 Antibkeokalani'nui-5/7/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News